Melphalan Tillomed

Melphalan Hydrochloride, the active ingredient in Melphalan Tillomed, is an alkylating agent (nitrogen mustard) presented as a sterile solution for intravenous use. It is employed in chemotherapy for certain hematologic and solid tumors.

GNH USA supplies Melphalan Tillomed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Melphalan acts as an alkylating chemotherapy agent targeting rapidly dividing cancer cells. - Multiple myeloma: helps reduce malignant plasma cells and improve disease control. - Ovarian cancer: used in combination regimens to shrink tumors and extend survival. - Melanoma: administered as part of treatment protocols for advanced disease. - Acute leukemias: contributes to remission induction by destroying leukemic blasts.

Adverse reactions vary in frequency and severity.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset common during treatment. - Myelosuppression: decreased blood cell counts leading to anemia, neutropenia, and thrombocytopenia. - Alopecia: hair loss affecting scalp and body hair. - Fatigue: persistent tiredness during therapy.

Serious or Rare Side Effects: - Severe infection: due to neutropenia and immune compromise. - Secondary malignancies: risk of therapy‑related cancers. - Pulmonary toxicity: rare interstitial pneumonitis. - Renal impairment: possible nephrotoxicity with high cumulative doses.

Use melphalan with careful clinical monitoring and appropriate supportive care. - Monitor blood counts: regular CBCs to detect myelosuppression. - Assess renal function: adjust therapy if creatinine clearance is reduced. - Evaluate hepatic function: liver impairment may affect drug metabolism. - Avoid in active severe infection: risk of worsening infection due to immunosuppression. - Pregnancy and lactation: contraindicated unless benefits outweigh risks; discuss with specialist. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Melphalan may interact with other drugs, requiring vigilance.

Major Interactions (Avoid): - Concurrent myelosuppressive agents: can exacerbate bone‑marrow toxicity. - High‑dose radiation therapy: increased risk of tissue damage. - Live vaccines: heightened risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - NSAIDs: may increase risk of renal toxicity. - Anticoagulants: enhanced bleeding tendency with thrombocytopenia. - Allopurinol: may affect uric acid metabolism during tumor lysis. - ACE inhibitors: potential additive renal effects. - CYP450 inhibitors: may modestly raise melphalan plasma levels.